Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307 to treat relapsing-remitting multiple sclerosis (RRMS).

Electron micrographs of the lumbar spinal cord showed remyelination in EAE-induced, Lingo1-knockout mice, but demyelination in wild-type control mice. Next, the authors tested whether inhibition ...

Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third ...

Our research focuses on the understanding of myelin regeneration (remyelination) and its failure during multiple sclerosis (MS). We aim to reveal how oligodendrocyte progenitor cell function is ...

reduced demyelination and accelerated remyelination. The data were presented at the joint meeting of the European Committee and Americas Committee for Research and Treatment in Multiple Sclerosis ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics ...